ProveIt Supplements

Independent, evidence-based supplement analysis.

✓ Not Sponsored

✓ No Paid Reviews

✓ Science-Based

Company

  • About Us
  • Our Methodology
  • Contact
  • Blog
  • Authors

Legal

  • Privacy Policy
  • Terms of Service
  • Medical Disclaimer
  • Affiliate Disclosure

Resources

  • All Categories
  • Ingredient Database
  • Browse Supplements
  • FAQ

© 2026 ProveIt Supplements. All rights reserved.

Medical Disclaimer: The information provided is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before starting any supplement regimen.

Prove It
Browse SupplementsBlogAuthorsAboutMethodologyFAQ
Get Your Personalized Supplement StackSupplement Stack Quiz
Menu
HomeBrowse SupplementsBlogAuthorsAboutMethodologyFAQ
Back

Puracol Feverfew

Also known as: Feverfew, Tanacetum parthenium L., Puracol Feverfew, Tanacetum parthenium

Overview

Feverfew, scientifically known as Tanacetum parthenium, is a medicinal herb traditionally used for migraine prevention and anti-inflammatory purposes. The primary active compound is parthenolide, along with other sesquiterpene lactones. Feverfew supplements are available in various forms, including dried leaf powder, alcoholic extracts, and CO₂ extracts. Research has largely focused on its efficacy in migraine prophylaxis and anti-inflammatory effects. While some studies, particularly those using dried powdered leaf extract, have shown favorable outcomes, higher-quality trials using alcoholic or CO₂ extracts have not consistently demonstrated significant benefits. The evidence base includes randomized controlled trials (RCTs) and systematic reviews, but results are inconsistent due to variability in extract types, dosages, and study quality. Therefore, the effectiveness of feverfew remains a topic of ongoing research and debate.

Benefits

Feverfew has been primarily studied for its potential in migraine prevention and anti-inflammatory effects. A Cochrane systematic review found insufficient evidence to conclusively support feverfew's superiority over placebo in reducing migraine frequency or severity. However, some trials using dried powdered leaf extract reported positive outcomes. Additionally, feverfew may offer anti-inflammatory benefits, with one small RCT suggesting improved grip strength in rheumatoid arthritis patients. In vitro studies also indicate potential antimicrobial activity, though the clinical relevance of this is unclear. Overall, while feverfew shows promise in certain areas, the evidence is not robust, and further research is needed to confirm its benefits.

How it works

Feverfew's mechanism of action is attributed to its active compound, parthenolide. Parthenolide may inhibit serotonin release from platelets and modulate 5-HT receptors, potentially reducing migraine triggers. The anti-inflammatory effects may involve the inhibition of cytokines such as IL-1, TNF-alpha, and interferon-gamma, as well as the downregulation of ICAM-1 expression on synovial fibroblasts. Additionally, parthenolide exhibits antimicrobial effects by inhibiting microbial growth in vitro. The absorption and bioavailability of feverfew can vary depending on the extract type, highlighting the importance of standardized parthenolide content in supplements.

Side effects

Feverfew is generally well-tolerated, but some side effects have been reported. Common side effects include mild gastrointestinal symptoms and mouth ulcers. Rare allergic reactions are also possible. Due to its mild blood-thinning effects, feverfew may interact with anticoagulants, increasing the risk of bleeding. It is contraindicated in pregnancy due to the potential for uterine stimulation. Long-term safety data are limited, and caution is advised with prolonged use. Individuals with known allergies to plants in the Asteraceae family (e.g., ragweed, chrysanthemums) should exercise caution when using feverfew.

Dosage

For migraine prevention, Canadian regulatory guidance suggests 125 mg/day of dried feverfew leaf containing at least 0.2% parthenolide. Clinical trials have used doses ranging from 50 to 143 mg/day of various extract forms. Standardization of parthenolide content is critical for reproducibility and consistent effects. Daily administration over several weeks (8–24 weeks) is typical in migraine studies. Due to the variability in extract types and parthenolide concentrations, it is essential to follow product-specific dosage recommendations and consult with a healthcare professional.

FAQs

Is feverfew effective for migraine prevention?

Evidence is inconclusive. Some studies show benefit with dried leaf extracts, but higher-quality trials with standardized extracts show no clear effect. More research is needed to confirm its efficacy.

Is feverfew safe?

Generally safe with mild side effects like gastrointestinal upset. Avoid in pregnancy and use caution with blood thinners due to potential interactions.

How long does it take to see effects from feverfew?

Benefits, if any, are typically assessed after 8 weeks or more of consistent daily use. It is not an acute treatment and requires a trial period to evaluate effectiveness.

Does the extract type of feverfew matter?

Yes, the type of extract can influence efficacy. Dried leaf powder may differ from alcoholic or CO₂ extracts. Standardized parthenolide content is crucial for consistent results.

Research Sources

  • https://pmc.ncbi.nlm.nih.gov/articles/PMC3210009/ – This Cochrane systematic review analyzed five double-blind RCTs involving 343 patients and found insufficient evidence to support feverfew's superiority over placebo for migraine prevention. The review noted that trials using dried leaf powder showed some benefit, while higher-quality trials with alcoholic and CO₂ extracts did not. The authors highlighted heterogeneity in extract types and doses as a limitation.
  • https://pubmed.ncbi.nlm.nih.gov/9950629/ – This systematic review of clinical trials on feverfew for migraine indicated mixed results, with some trials showing a reduction in migraine frequency, but the overall evidence was not definitive. The review pointed out limitations such as small sample sizes and variable methodologies across the included studies. The authors concluded that more rigorous research was needed to determine the efficacy of feverfew for migraine prevention.
  • https://www.drugs.com/npp/feverfew.html – This resource summarizes findings from a double-blind, randomized, placebo-controlled trial involving 41 women with rheumatoid arthritis. The trial found a significant improvement in grip strength with feverfew (70-86 mg) over a 6-week period, but no other parameters improved. The summary notes that the parthenolide content was not standardized in the feverfew preparation used in the study.
  • https://www.webmd.com/vitamins/ai/ingredientmono-933/feverfew – WebMD provides general information on feverfew, including its uses, potential benefits, and safety considerations. It highlights feverfew's traditional use for migraine prevention and notes that while some studies suggest benefits, the evidence is not conclusive. The resource also mentions potential side effects and interactions with other medications.
  • https://www.healthline.com/nutrition/feverfew – Healthline offers an overview of feverfew, discussing its potential health benefits and uses. It mentions that feverfew has been traditionally used for migraine prevention and may have anti-inflammatory properties. The article also provides information on dosage and potential side effects, emphasizing the importance of consulting with a healthcare professional before using feverfew.

Supplements Containing Puracol Feverfew

MigreLief Triple Therapy with Puricol by Akeso
75

MigreLief Triple Therapy with Puricol

Akeso

Score: 75/100
Children's MigreLief Triple Therapy With Puracol by Akeso
78

Children's MigreLief Triple Therapy With Puracol

Akeso

Score: 78/100
MigreLief Triple Therapy with Puracol by Akeso
78

MigreLief Triple Therapy with Puracol

Akeso

Score: 78/100
Children's MigreLief by Akeso
75

Children's MigreLief

Akeso

Score: 75/100
MigreLief Triple Therapy with Puracol by Akeso
68

MigreLief Triple Therapy with Puracol

Akeso

Score: 68/100
MigreLief+M by Akeso
70

MigreLief+M

Akeso

Score: 70/100
MigreLief-NOW by Akeso
65

MigreLief-NOW

Akeso

Score: 65/100